MRCT Phase III study
evaluated EV vaccine
MVC is a biopharmaceutical company focusing on the development and mass production of vaccines and biologics. We have PIC/S GMP certified cell culture commercial mass production capabilities, and target global and regional infectious diseases to develop novel vaccines and affordable biosimilar drugs via international alliances.
We are based in Taiwan and human health is our priority. Since MVC was established, we are dedicated to developing countermeasures for the prevention and treatment of emerging infectious diseases such as COVID-19, Enterovirus A71, Dengue, and Influenza vaccines. Our achievements to date prove that our products and technologies deliver.
We believe the right to health is a fundamental part of our human rights and also the foundation of global development. Vaccines and biologics are key strategies to approach the goal. We are continuing to provide safe, effective, and qualified medical products and aim to become the R&D and mass production hub in the Asia-Pacific region. We are introducing our products to the world to protect people from the threat of numerous diseases.
As we reflect on our past,
we will continue to strive for a better future.